These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14989461)

  • 1. Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies.
    Brady RO
    Acta Paediatr Suppl; 2003 Dec; 92(443):19-24. PubMed ID: 14989461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
    Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
    PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gaucher disease, Fabry disease and mucopolysaccharidosis type I--how can the rheumatologist recognise these patients?].
    Manger B; Menge E; Schaefer R; Haase C; Seidel J; Michels H
    Z Rheumatol; 2006 Feb; 65(1):32, 34-43. PubMed ID: 16467949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
    Fabrega S; Lehn P
    J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease with special reference to neurological manifestations.
    Banerjee TK
    Eur Rev Med Pharmacol Sci; 2004; 8(6):275-81. PubMed ID: 15745387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lysosomal storage disorders - Fabry disease and Gaucher disease].
    Segura Schmitz L; Hennermann JB; Lollert A
    Dtsch Med Wochenschr; 2024 Oct; 149(21):1263-1269. PubMed ID: 39384207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances and novel treatments for sphingolipidoses.
    Arenz C
    Future Med Chem; 2017 Sep; 9(14):1687-1700. PubMed ID: 28857617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses.
    Ferraz MJ; Kallemeijn WW; Mirzaian M; Herrera Moro D; Marques A; Wisse P; Boot RG; Willems LI; Overkleeft HS; Aerts JM
    Biochim Biophys Acta; 2014 May; 1841(5):811-25. PubMed ID: 24239767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme Replacement Therapy for Lysosomal Storage Diseases.
    Kleppin S
    J Infus Nurs; 2020; 43(5):243-245. PubMed ID: 32881810
    [No Abstract]   [Full Text] [Related]  

  • 10. Current enzyme replacement therapy for the treatment of lysosomal storage diseases.
    Lim-Melia ER; Kronn DF
    Pediatr Ann; 2009 Aug; 38(8):448-55. PubMed ID: 19725195
    [No Abstract]   [Full Text] [Related]  

  • 11. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study.
    Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
    Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
    Dandana A; Ben Khelifa S; Chahed H; Miled A; Ferchichi S
    Pathobiology; 2016; 83(1):13-23. PubMed ID: 26588331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging strategies for the treatment of hereditary metabolic storage disorders.
    Brady RO
    Rejuvenation Res; 2006; 9(2):237-44. PubMed ID: 16706651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New prospects for the treatment of lysosomal storage diseases.
    Schiffmann R; Brady RO
    Drugs; 2002; 62(5):733-42. PubMed ID: 11929328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different diseases, different needs: Patient preferences for gene therapy in lysosomal storage disorders, a probabilistic threshold technique survey.
    Corazolla EM; Eskes ECB; Veldwijk J; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
    Orphanet J Rare Dis; 2024 Oct; 19(1):367. PubMed ID: 39363355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme reconstitution/replacement therapy for lysosomal storage diseases.
    Burrow TA; Hopkin RJ; Leslie ND; Tinkle BT; Grabowski GA
    Curr Opin Pediatr; 2007 Dec; 19(6):628-35. PubMed ID: 18025928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home therapy for lysosomal storage disorders.
    Hughes DA; Mlilligan A; Mehta A
    Br J Nurs; 2007 Dec 13-2008 Jan 9; 16(22):1384, 1386-9. PubMed ID: 18361386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement and beyond.
    Desnick RJ
    J Inherit Metab Dis; 2001 Apr; 24(2):251-65. PubMed ID: 11405344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous enzyme replacement therapy: better in home or hospital?
    Milligan A; Hughes D; Goodwin S; Richfield L; Mehta A
    Br J Nurs; 2006 Mar 23-Apr 12; 15(6):330-3. PubMed ID: 16628169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.